Janssen Research & Development seeks to drive innovation and deliver transformational medicines for the treatment of diseases in six therapeutic areas: neuroscience, cardiovascular diseases and metabolism, infectious diseases, immunology, oncology and pulmonary hypertension. In these areas, Janssen aims to address and solve unmet medical needs through the development of small and large molecules, as well as vaccines. The Janssen campus in Beerse (Belgium) has a unique ecosystem covering the complete drug development life cycle, with all capabilities from basic science to market access on one campus. The integrated environment of our campus gives our people the chance to experience many different aspects of drug development throughout their career. It has a successful track record of over sixty years of drug discovery and development and is one of the most important innovation engines of the Janssen group worldwide.
A handful of startups are employing artificial intelligence technologies and big data in an attempt to diagnose dementia, particularly Alzheimer's disease. The effort could lead to better interventions and even therapeutic drugs if it becomes possible to detect cognitive decline before it really starts. The benefits to society – not to mention market potential – for the early detection of dementia and Alzheimer's disease are huge. According to the World Health Organization, there were 47.5 million people worldwide with dementia in 2015, with 7.7 million new cases each year. The total number of people with dementia is projected to reach 75.6 million in 2030 and almost triple by 2050 to 135.5 million.
ALS, Amyotrophic Lateral Sclerosis, is a progressive nervous system disease that affects nerve and muscle function. Currently, treatments can't reverse the damage of ALS but progression of symptoms and prevent complications. There is no cure for ALS and it can eventually become fatal. The ALS Association is providing funding to support GNS' use of its artificial intelligence (AI) technology to create a disease model. "GNS will receive and process data from the Answer ALS dataset which includes whole genome sequencing, proteomics, RNA sequencing, epigenomics, lipidomics, metabolomics and clinical information.
Amongst his other amazing projects, Elon Musk wants to help hook us up to our brains. According to a recent report in The Wall Street Journal, he is backing an operation called Neuralink, which is experimenting with putting electrodes in our brains to enhance their function. The benefits for a whole variety of conditions are obvious, but it poses a question: Is this venture into brain technology the start of the next space race? We have conquered many parts of our exterior world, but with lightning-fast improvements in AI technology, will human brains now be in a race to keep up with their robot AI cousins? This "neural lace" technology has so many real-world applications, and it could eventually mean that an entirely different "class" of people emerges -- but I would just like to ask the question whether it would be entirely healthy to have intimate access to every single thought that has ever crossed our mind.
Would you really want to know? Amongst his other amazing projects, Elon Musk wants to help hook us up to our brains. According to a recent report in the Wall Street Journal, he is backing an operation called Neuralink, which is experimenting with putting electrodes in our brains to enhance their function. Is this venture into brain technology the start of the next space race? We have conquered many parts of our exterior world, but with lightening fast improvements in A.I. technology, will human brains now be in a race to keep up with their robot A.I. cousins?